holds a doctorate in pharmacy and has many years of experience in the field of evidence-based medicine and the benefit assessment of medicinal products.
After studying pharmacy and completing her doctorate in the field of cardiovascular diseases, she began her professional career as a consultant pharmacist at BARMER in Bavaria. In this role, she advised on the economic aspects of pharmaceutical supply and health policy issues.
From 2011 to 2024, Dr. Behring worked at the Federal Joint Committee (G-BA) in the Pharmaceuticals Subcommittee. Since the introduction of the Act on the Reform of the Market for Medicinal Products (AMNOG), she has been involved in the implementation of the early benefit assessment of medicinal products in Germany. She also played a key role in including Germany in the European benefit assessment procedure and advocated the close coordination between national and European assessment and consultation processes.
Before studying pharmacy, Dr. Behring gained practical experience as a physiotherapist in both outpatient and inpatient settings.
Since 2024, she has been working for the German Association Pharma Deutschland, where she deals with key issues such as Health Technology Assessment (HTA) in Germany and Europe, reimbursement amounts as well as innovation and research in the pharmaceutical sector.